Exenatide: renal failure. Risk-benefit balance becoming uncertain.
D003362:Cost-Benefit Analysis; D005060:Europe; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D010455:Peptides / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced*; D014688:Venoms / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide